Global Information
회사소개 | 문의 | 비교리스트

세계의 항고혈압제 시장 예측(2019-2028년)

Global Antihypertensive Drugs Market Forecast 2019-2028

리서치사 Inkwood Research
발행일 2020년 06월 상품 코드 943442
페이지 정보 영문 188 Pages
가격
US $ 2,500 ₩ 2,940,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 되지 않으며, 인쇄 또한 불가능합니다.
US $ 3,000 ₩ 3,528,000 PDF (Multi User License) help
동일 사업장(소재지) 내 5명까지 이용가능한 라이센스입니다. PDF 파일은 Copy & Paste가 되지 않습니다. 인쇄는 1명당 1회에 한해 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,293,000 PDF (Enterprisewide License) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 항고혈압제 시장 예측(2019-2028년) Global Antihypertensive Drugs Market Forecast 2019-2028
발행일 : 2020년 06월 페이지 정보 : 영문 188 Pages

2019-2028년간 세계 항고혈압제 시장은 3.21%의 연평균 복합 성장률(CAGR)로 성장할 것으로 추정되고 있습니다. 고혈압 유병률 급증, 고혈압 관련 합병증의 인식 향상, 노인 인구 및 좌식 생활 증가가 시장 성장을 견인하는 주요인이 되고 있습니다. 그러나 최근의 특허 만료는 항고혈압제 시장 성장을 방해할 것으로 예상됩니다. 저렴한 제네릭 시장 진입으로 이어져 시장의 확대를 제한할 것으로 전망됩니다.

세계의 항고혈압제(Antihypertensive Drugs) 시장을 조사했으며, 시장 개요, 시장 성장 영향요인 분석, 부문 및 지역별 분석 및 예측, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

제1장 조사 범위와 조사 방법

  • 조사 목적
  • 조사 범위
  • 조사 방법
  • 전제조건 및 제한

제2장 개요

  • 시장 규모 및 추정
  • 시장 개요

제3장 시장 역학

  • 시장 정의
  • 주요 시장 성장 촉진요인
    • 세계적인 고혈압 유병률 상승
    • 가처분 소득 및 의료 지출 급증
    • 노인 인구 증가
  • 주요 시장 성장 억제요인
    • 특허 만료
    • 제품 출시 지연

제4장 주요 분석

  • Porter's Five Forces 분석
  • 규제 프레임워크
  • 시장 기회 매트릭스
  • 벤더 상황
  • 주요 투자 인사이트

제5장 시장 : 약제 클래스별

  • 칼슘 채널 차단제
  • ACE 억제제
  • 베타 아드레날린 차단제
  • 이뇨제
  • 혈관 확장제
  • 기타 약제 클래스

제6장 시장 : 최종사용자별

  • 병원 약국
  • 소매 약국
  • E-COMMERCE 웹 사이트 및 온라인 약국

제7장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 러시아
    • 벨기에
    • 폴란드
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 한국
    • 태국
    • 인도네시아
    • 베트남
    • 기타 아시아태평양
  • 기타 지역
    • 라틴아메리카
    • 중동 및 아프리카

제8장 기업 개요

  • ALLERGAN PLC
  • ASPIRE BARIATRICS INC
  • ASTRAZENECA PLC
  • BIO-RAD LABORATORIES INC
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • DAIICHI SANKYO COMPANY LIMITED
  • HILL-ROM HOLDINGS INC
  • JOHNSON & JOHNSON
  • LUPIN LIMITED
  • MEDTRONIC PLC
  • MERCK & CO INC
  • NOVARTIS AG
  • PFIZER INC
  • SANOFI
  • SUN PHARMACEUTICAL INDUSTRIES LTD.(RANBAXY LABORATORIES)
LSH 20.07.07

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - ANTIHYPERTENSIVE DRUGS
  • TABLE 2: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 3: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 4: GLOBAL CALCIUM CHANNEL BLOCKERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: GLOBAL CALCIUM CHANNEL BLOCKERS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 6: GLOBAL ACE INHIBITORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: GLOBAL ACE INHIBITORS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 8: GLOBAL BETA-ADRENERGIC BLOCKERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: GLOBAL BETA-ADRENERGIC BLOCKERS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 10: GLOBAL DIURETICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: GLOBAL DIURETICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 12: GLOBAL VASODILATORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 13: GLOBAL VASODILATORS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 14: GLOBAL OTHER DRUG CLASS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 15: GLOBAL OTHER DRUG CLASS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 16: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 17: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 18: GLOBAL HOSPITAL PHARMACY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 19: GLOBAL HOSPITAL PHARMACY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 20: GLOBAL RETAIL PHARMACY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 21: GLOBAL RETAIL PHARMACY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 22: GLOBAL E-COMMERCE WEBSITES & ONLINE DRUG STORES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 23: GLOBAL E-COMMERCE WEBSITES & ONLINE DRUG STORES MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 24: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 25: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 26: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 27: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 28: EUROPE ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 29: EUROPE ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 30: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 31: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 32: REST OF WORLD ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 33: REST OF WORLD ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: NUMBER OF AGING POPULATION BY REGION 2017& 2050 (IN MILLION)
  • FIGURE 2: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 3: OPPORTUNITY MATRIX
  • FIGURE 4: VENDOR LANDSCAPE
  • FIGURE 5: KEY INVESTMENT INSIGHTS
  • FIGURE 6: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, IN 2019
  • FIGURE 7: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY CALCIUM CHANNEL BLOCKERS, 2019-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY ACE INHIBITORS, 2019-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY BETA-ADRENERGIC BLOCKERS, 2019-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY DIURETICS, 2019-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY VASODILATORS, 2019-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY OTHER DRUG CLASS, 2019-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY END-USER, IN 2019
  • FIGURE 14: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY HOSPITAL PHARMACY, 2019-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY RETAIL PHARMACY, 2019-2028 (IN $ MILLION)
  • FIGURE 16: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY E-COMMERCE WEBSITES & ONLINE DRUG STORES, 2019-2028 (IN $ MILLION)
  • FIGURE 17: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 18: THE UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 19: CANADA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 20: EUROPE ANTIHYPERTENSIVE DRUGS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 21: THE UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 22: FRANCE ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 23: GERMANY ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 24: ITALY ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 25: RUSSIA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 26: BELGIUM ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 27: POLAND ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 28: REST OF EUROPE ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 29: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 30: CHINA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 31: JAPAN ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 32: INDIA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 33: AUSTRALIA & NEW ZEALAND ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 34: SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 35: THAILAND ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 36: INDONESIA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 37: VIETNAM ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 38: REST OF ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 39: REST OF WORLD ANTIHYPERTENSIVE DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 40: LATIN AMERICA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 41: MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)

KEY FINDINGS

During the forecast period from 2019 to 2028, the global antihypertensive drugs market is estimated to grow with a CAGR of 3.21%. A surge in the prevalence of hypertension and a rise in awareness of complications related to hypertension, as well as an increase in the geriatric population and sedentary lifestyle, are primary factors that drive the market growth.

MARKET INSIGHTS

The growth of the global antihypertensive drugs market is propelled by a worldwide surge in the prevalence of hypertension. Antihypertensive drugs are used to treat patients suffering from hypertension, a medical condition that involves a rise in blood pressure in the arteries. Moreover, an individual who suffers from hypertension is very susceptible to other complications like aneurysm and heart failure. Thus, hypertension requires early diagnosis as well as management by using antihypertensive drugs. The frequency of cardiovascular diseases among the geriatric population is predicted to increase at an alarming rate. Therefore, a steady and rapid rise in the geriatric population is among the key drivers of the antihypertensive drugs market as the aging population is highly vulnerable to high blood pressure. This would further be beneficial for the global antihypertensive drugs market growth as aged individuals continue to become prone to hypertension and other cardiovascular complications. Conversely, an upsurge in research related to antihypertensive drugs in developing economies, would offer profitable prospects through the forecast period. However, recent patent expirations are expected to hinder the growth of the antihypertensive drugs market. They lead to the entrance of cheap generics in the market and thus limit market expansion. For instance, Bystolic, an antihypertensive drug by Allergan, will lose patent protection in 2021.

REGIONAL INSIGHTS

The geographical segmentation of the global antihypertensive drugs market includes Asia Pacific, Europe, North America, and the rest of the world. According to Inkwood Research, North America dominated the antihypertensive drugs market in 2019, possessing a revenue share of 35.02%. It is anticipated that the region will continue this trend throughout the forecast period, as a result of a rise in the prevalence of hypertension and chronic kidney disorders. Additionally, the presence of major companies like Johnson & Johnson propels the antihypertensive drugs market growth in the North America region.

COMPETITIVE INSIGHTS

An intense rivalry exists among the major enterprises in the market, and the degree of competition is extensive. Allergan PLC, Aspire Bariatrics Inc, Bio-Rad Laboratories Inc, Johnson & Johnson, Sanofi, etc. are among the renowned companies in the market.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. GROWING PREVALENCE OF HYPERTENSION ACROSS THE GLOBE
    • 3.2.2. SURGE IN DISPOSABLE INCOME AND HEALTHCARE SPENDING
    • 3.2.3. RISING AGING POPULATION
  • 3.3. KEY RESTRAINTS
    • 3.3.1. PATENT EXPIRATIONS
    • 3.3.2. DELAY IN PRODUCT LAUNCHES

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. REGULATORY FRAMEWORK
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE
  • 4.5. KEY INVESTMENT INSIGHTS

5. MARKET BY DRUG CLASS

  • 5.1. CALCIUM CHANNEL BLOCKERS
  • 5.2. ACE INHIBITORS
  • 5.3. BETA-ADRENERGIC BLOCKERS
  • 5.4. DIURETICS
  • 5.5. VASODILATORS
  • 5.6. OTHER DRUG CLASS

6. MARKET BY END-USER

  • 6.1. HOSPITAL PHARMACY
  • 6.2. RETAIL PHARMACY
  • 6.3. E-COMMERCE WEBSITES & ONLINE DRUG STORES

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. THE UNITED STATES
    • 7.1.2. CANADA
  • 7.2. EUROPE
    • 7.2.1. THE UNITED KINGDOM
    • 7.2.2. FRANCE
    • 7.2.3. GERMANY
    • 7.2.4. ITALY
    • 7.2.5. RUSSIA
    • 7.2.6. BELGIUM
    • 7.2.7. POLAND
    • 7.2.8. REST OF EUROPE
  • 7.3. ASIA PACIFIC
    • 7.3.1. CHINA
    • 7.3.2. JAPAN
    • 7.3.3. INDIA
    • 7.3.4. AUSTRALIA & NEW ZEALAND
    • 7.3.5. SOUTH KOREA
    • 7.3.6. THAILAND
    • 7.3.7. INDONESIA
    • 7.3.8. VIETNAM
    • 7.3.9. REST OF ASIA PACIFIC
  • 7.4. REST OF WORLD
    • 7.4.1. LATIN AMERICA
    • 7.4.2. MIDDLE EAST & AFRICA

8. COMPANY PROFILES

  • 8.1. ALLERGAN PLC
  • 8.2. ASPIRE BARIATRICS INC
  • 8.3. ASTRAZENECA PLC
  • 8.4. BIO-RAD LABORATORIES INC
  • 8.5. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • 8.6. DAIICHI SANKYO COMPANY LIMITED
  • 8.7. HILL-ROM HOLDINGS INC
  • 8.8. JOHNSON & JOHNSON
  • 8.9. LUPIN LIMITED
  • 8.10. MEDTRONIC PLC
  • 8.11. MERCK & CO INC
  • 8.12. NOVARTIS AG
  • 8.13. PFIZER INC
  • 8.14. SANOFI
  • 8.15. SUN PHARMACEUTICAL INDUSTRIES LTD. (RANBAXY LABORATORIES)
Back to Top
전화 문의
F A Q